Recent Updates
Recently added Catalysts
PHGE Positive Sentiment Score: 60/100

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Key Takeaway: BiomX Inc. will host a conference call and webcast on May 15, 2025, at 2:00 p.m. ET to report its financial results for the first quarter of 2025 and provide updates on its business and programs. The company specializes in developing natural and engineered phage therapies to target and combat harmful bacteria, addressing chronic diseases with significant unmet needs. The event aims to keep investors informed about the company's progress and financial health.

Market Sentiment Analysis

POSITIVE FACTORS

  • BiomX is advancing novel phage therapies targeting pathogenic bacteria.
  • The company is hosting a conference to update stakeholders on financial results.
  • BiomX is addressing substantial unmet medical needs with its therapies.

Full Press Release Details

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
Head Corporate Communications

Frequently Asked Questions

What is BiomX Inc. focused on developing?

BiomX Inc. focuses on developing natural and engineered phage therapies targeting harmful bacteria.

When is BiomX's conference call scheduled?

The conference call is scheduled for May 15, 2025, at 2:00 p.m. ET.

How can I participate in BiomX's conference call?

Join by dialing 1-877-407-0724 for U.S. callers or +1 201-389-0898 internationally.

Where can I find the live audio webcast of the call?

The live audio webcast will be available in the Investors section of BiomX's website.

What platform does BiomX use for phage treatment customization?

BiomX uses its BOLT platform to customize phage compositions against specific bacterial targets.

Last updated: May 8, 2025